Coherus Oncology (CHRS) Cash & Current Investments (2013 - 2026)

Coherus Oncology (CHRS) has 14 years of Cash & Current Investments data on file, last reported at $167.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 102.7% year-over-year to $167.0 million; the trailing twelve-month figure through Mar 2026 stood at $167.0 million (up 102.7% YoY), and the FY2025 full-year result was $172.1 million, up 36.62% from the prior year.
• Cash & Current Investments fell to $167.0 million in Q1 2026, from $172.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $325.7 million in Q1 2022 to a low of $82.4 million in Q1 2025.
• A 5-year average of $182.1 million and a median of $167.0 million in 2026 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 102.81% in 2024 and sank 68.28% in 2025, its largest moves.
• Tracing CHRS's Cash & Current Investments over 5 years: stood at $191.7 million in 2022, then tumbled by 38.57% to $117.7 million in 2023, then rose by 7.0% to $126.0 million in 2024, then jumped by 36.62% to $172.1 million in 2025, then fell by 2.95% to $167.0 million in 2026.
• Business Quant data shows CHRS's Cash & Current Investments at $167.0 million in Q1 2026, $172.1 million in Q4 2025, and $191.7 million in Q3 2025.